Influence of benzodiazepines on antiparkinsonian drug treatment in levodopa users

Acta Neurologica Scandinavica
D A M C van de VijverA de Boer

Abstract

Animal studies showed that benzodiazepines decrease the concentration of dopamine in the striatum. Benzodiazepines may therefore affect the treatment of Parkinson's disease. This study determined whether start of a benzodiazepine in patients on levodopa was followed by a faster increase of antiparkinsonian drug treatment. Data came from the PHARMO database, which includes information on drug dispensing for all residents of six Dutch cities. Selected were all patients aged 55 years and older who used levodopa for at least 360 days. The rate of increase of antiparkinsonian drug treatment was compared between starters of a benzodiazepine and controls who did not start a benzodiazepine with the use of Cox's proportional hazard model. Identified were 45 benzodiazepine starters (27 women, mean age 76.4 years) and 169 controls (83 women, 74.3 years). Antiparkinsonian drug treatment increased faster in the benzodiazepine group; relative risk was 1.44 (95% confidence interval 0.80-2.59). This study has not found any statistically significant increase in antiparkinsonian drug treatment when a benzodiazepine was started in a small population of chronic levodopa users.

References

Apr 1, 1992·Journal of Epidemiology and Community Health·R M HeringsG Nap
Mar 1, 1992·Journal of Neurology, Neurosurgery, and Psychiatry·A J HughesA J Lees
Nov 1, 1989·Archives of Internal Medicine·L G Miller, J Jankovic
Jan 1, 1989·Movement Disorders : Official Journal of the Movement Disorder Society·E PourcherY Agid
Sep 1, 1987·Archives of Neurology·W C Koller, G Herbster
Dec 19, 1970·Lancet·K R HunterD R Laurence
Feb 1, 1982·Annals of Internal Medicine·S Yosselson-Superstine, A G Lipman
Jan 1, 1997·Movement Disorders : Official Journal of the Movement Disorder Society·A Negrotti, S Calzetti
Apr 26, 1997·Lancet·A DanieleP Bartolomeo
Jul 1, 1997·Movement Disorders : Official Journal of the Movement Disorder Society·M MerelloR Leiguarda
May 20, 1998·Pharmacology, Biochemistry, and Behavior·M J MattilaT Seppälä
Aug 17, 1999·Journal of Neurology, Neurosurgery, and Psychiatry·D E BatemanC D Marsden
Sep 16, 1999·Journal of Neurology, Neurosurgery, and Psychiatry·D AarslandJ L Cummings
Dec 10, 1999·Movement Disorders : Official Journal of the Movement Disorder Society·E TandbergK Karlsen
Aug 6, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·E RůzickaP Busek
Oct 16, 2001·Pharmacy World & Science : PWS·D A van de VijverA de Boer

❮ Previous
Next ❯

Citations

May 2, 2006·Journal of Neurology·Dirk WoitallaThomas Müller

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Related Papers

British Journal of Anaesthesia
D J Deardon, G L Bird
Developmental Medicine and Child Neurology
S Mackereth
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
G ArabiaA Quattrone
© 2022 Meta ULC. All rights reserved